ArticleBritish journal of pharmacology2008
Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium.
Article in British journal of pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 53 citations in OpenAlex.
- Ranolazine for improving coronary microvascular function in patients with nonobstructive coronary artery disease: a systematic review and meta-analysis with a trial sequential analysis of randomized controlled trials.Quantitative imaging in medicine and surgery · 2024Article
- Improvement of Vascular Insulin Sensitivity by Ranolazine.International journal of molecular sciences · 2023Article
- Facilitation of Insulin Effects by Ranolazine in Astrocytes in Primary Culture.International journal of molecular sciences · 2022Article
- Identification and Quantification of Glutathionylated Cysteines under Ischemic Stress.Journal of proteome research · 2021Article
- Article
- The arrhythmogenic consequences of increasing late INa in the cardiomyocyte.Cardiovascular research · 2013Review
- Electrical plasticity and cardioprotection in myocardial ischemia--role of selective sodium channel blockers.Clinical cardiology · 2013Review
- 18β-Glycyrrhetinic acid preferentially blocks late Na current generated by ΔKPQ Nav1.5 channels.Acta pharmacologica Sinica · 2012Article
- Cardiac calmodulin kinase: a potential target for drug design.Current medicinal chemistry · 2011Review
- Ranolazine selectively blocks persistent current evoked by epilepsy-associated Naν1.1 mutations.British journal of pharmacology · 2010Article
- F 15845, a new blocker of the persistent sodium current prevents consequences of hypoxia in rat femoral artery.British journal of pharmacology · 2010Article
- Selective inhibition of persistent sodium current by F 15845 prevents ischaemia-induced arrhythmias.British journal of pharmacology · 2010Article
- Riluzole protects against cardiac ischaemia and reperfusion damage via block of the persistent sodium current.British journal of pharmacology · 2010Article
- New developments in atrial antiarrhythmic drug therapy.Nature reviews. Cardiology · 2010Review
- Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine.Journal of molecular and cellular cardiology · 2009Article
- Atrial-selective sodium channel block for the treatment of atrial fibrillation.Expert opinion on emerging drugs · 2009Review
- F 15845 inhibits persistent sodium current in the heart and prevents angina in animal models.British journal of pharmacology · 2009Article
- Review
- Ranolazine preserves and improves left ventricular ejection fraction and autonomic measures when added to guideline-driven therapy in chronic heart failure.Heart internationalArticle
- Ranolazine improves autonomic balance in heart failure when added to guideline-driven therapy.Heart internationalArticle
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This commentary on the review by DA Saint in the current issue of the British Journal of Pharmacology focuses on the pathological role of late I(Na) in the heart, the evidence supporting inhibition of late I(Na) as a therapeutic target in ischaemic heart disease, and the therapeutic applications and challenges for development of new late I(Na) inhibitors. Recent reports from a large clinical outcome trial (MERLIN) of ranolazine, a drug known to inhibit late I(Na), indicated that it was safe and reduced recurrent ischaemia and arrhythmic activity. In combination with other results indicating that inhibition of late I(Na) reduces ischaemia, myocardial Ca(2+) overload, and electrical and mechanical dysfunction when late I(Na) is increased, the new clinical trial results suggest that reduction of cardiac late I(Na) is safe and therapeutically beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.